Jan Lundberg ran Lilly Research Laboratories, the research arm of Eli Lilly (LLY), from 2010 to 2018; the company now makes the weight-loss drug Zepbound. In E.B. Solomont's item for Friday's Mansion section on the roughly 117-acre Jackson Hole, Wyo., estate he's just sold, the line that matters isn't about the view. It's about the stock. One reason the couple could afford the place, he said, was the progress of the Lilly portfolio and "the shares I got from the company with time." Now he and his wife, Ingeborg, based mainly in Fort Lauderdale, Fla., are buying a home in Sweden, and the Wyoming estate has gone for close to its $39.5 million asking price, near the top of what the valley has seen. That's the arc of employer stock in one paragraph: earned, turned into land, turned into a move.
The property is the kind of thing zoning no longer lets you build. The estate sits on top of East Gros Ventre Butte and includes several residences. The main house, built in 2009, is roughly 12,700 square feet of log, stone and glass with five bedrooms and an indoor pool, and the whole compound runs to about 18,000 square feet of living space — far more, says listing agent Latham Jenkins of Live Water Properties, than Jackson Hole's zoning now allows for a new house. A conservation easement keeps about 70% of the land off-limits to development. The Lundbergs bought in 2021; the only earlier figure the Journal gives is a last asking price of $33.9 million, not what they paid, so we won't guess at a gain. Buyer's agent Morgan Bruemmer of the Clear Creek Group wouldn't name the client, saying only that it isn't the buyer's first home in Jackson. For scale, Redfin puts the town of Jackson's median single-family price at $2.75 million for the three months to Aug. 31, up 21.5% in a year.
Scarcity by statute
Two things help explain a price of about $39.5 million, and neither is the pool. The first is a size that, by the listing agent's account, couldn't be permitted today, which makes the existing square footage a grandfathered asset. The second is the easement: 70% of the land kept open, a restriction that typically runs with the land and, in a valley that prizes empty, reads as a feature rather than a defect. Restrictions can add value as well as subtract it. Lilly (LLY), for the record, sits in 23 house books, held at weight, nothing added; a former executive's house sale says nothing about the shares, and Dr. Lundberg left his post in 2018, so this isn't a Zepbound story either.
Our read
Investments/Risk (IN04), with a Retirement (M10) echo. The planning point sits under Lundberg's own sentence: equity pay helped build the wealth, and a house is what that wealth looks like once it's no longer Lilly stock. That's the whole discipline for anyone paid in employer shares — a research chief, a mid-level engineer with restricted stock, a teacher's spouse at a company with a stock plan. Your paycheck, your health coverage and a good part of your net worth already ride on one employer; letting your savings ride on it too is concentration by default, not by choice. The question isn't whether to diversify but on what schedule: a standing rule to sell a slice at each vest or each year, in a tax bracket you can stand, rather than one lump decision in a year the stock's done well — or badly. The Journal doesn't say whether, when or how much he sold; what it shows is the end state, which is the point.
Hold. LLY stays at weight, and the house tells you nothing about the stock. If more than a modest slice of your net worth is in the company that signs your paycheck, put a number on it and a date on the next sale — in the review, on a quiet day, not the morning after the shares move. That's the umbrella bought before the forecast, not after.